Gastrointestinal Findings and Malignancy Diagnoses Recorded During the Follow-Up Period in Adults Receiving Intravenous Iron Therapy: A Descriptive Retrospective Cohort Study

Background/Objectives: Gastrointestinal findings and malignancy diagnoses recorded during follow-up were evaluated in adults receiving intravenous (IV) iron in routine clinical care. Methods: This single-center retrospective cohort included 1164 adults treated between 2015 and 2025. Hospital and e-Nabız records were reviewed through 22 October 2026. Iron deficiency anemia (IDA) required anemia and ferritin < 30 ng/mL. Physician-confirmed malignancy diagnoses and available pathology documentation were assessed separately. Associations were examined using Firth logistic regression. Results: Among 1116 patients with post-infusion records, median follow-up was 38.2 months. The IDA subgroup included 424 patients. Endoscopy records from any period were available for 341 patients, and post-infusion gastrointestinal mucosal histology for 198. Gastric atrophy was reported in 139/161 evaluable patients and intestinal metaplasia in 63/165. The combined diagnostic outcome was recorded after infusion in 46 patients: 15 gastrointestinal carcinomas, 22 non-gastrointestinal solid malignancies, and nine hematologic neoplasms. Full pathology reports documenting malignancy were available for 15 patients; 23 diagnoses were recorded more than one year after infusion. Among 1099 patients in the comparative analysis, male sex was associated with recorded malignancy diagnoses (adjusted odds ratio, 6.04; 95% confidence interval, 3.29–11.42; q < 0.001). No baseline laboratory variable was significantly associated with recorded malignancy diagnoses after correction for multiple testing. Conclusions: Gastrointestinal findings and malignancy diagnoses were documented in this treatment cohort. The association with male sex requires independent confirmation. These findings do not establish cancer incidence or a causal effect of IV iron.

Authors

Publication Details

Journal
Diagnostics
Published
2026-11-17
DOI
https://doi.org/10.3390/diagnostics16223830
Primary Topic
Iron Metabolism and Disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Gastrointestinal Findings and Malignancy Diagnoses Recorded During the Follow-Up Period in Adults Receiving Intravenous Iron Therapy: A Descriptive Retrospective Cohort Study

Engin Kelkitli, Fikriye Esra Gürses Ulubay, Eda Nur Yaman, Mehmet Turgut
1 links
Diagnostics
Iron Metabolism and Disorders
article

Gastrointestinal Findings and Malignancy Diagnoses Recorded During the Follow-Up Period in Adults Receiving Intravenous Iron Therapy: A Descriptive Retrospective Cohort Study

Engin Kelkitli, Fikriye Esra Gürses Ulubay, Eda Nur Yaman, Mehmet Turgut
article en

Abstract

Background/Objectives: Gastrointestinal findings and malignancy diagnoses recorded during follow-up were evaluated in adults receiving intravenous (IV) iron in routine clinical care. Methods: This single-center retrospective cohort included 1164 adults treated between 2015 and 2025. Hospital and e-Nabız records were reviewed through 22 October 2026. Iron deficiency anemia (IDA) required anemia and ferritin < 30 ng/mL. Physician-confirmed malignancy diagnoses and available pathology documentation were assessed separately. Associations were examined using Firth logistic regression. Results: Among 1116 patients with post-infusion records, median follow-up was 38.2 months. The IDA subgroup included 424 patients. Endoscopy records from any period were available for 341 patients, and post-infusion gastrointestinal mucosal histology for 198. Gastric atrophy was reported in 139/161 evaluable patients and intestinal metaplasia in 63/165. The combined diagnostic outcome was recorded after infusion in 46 patients: 15 gastrointestinal carcinomas, 22 non-gastrointestinal solid malignancies, and nine hematologic neoplasms. Full pathology reports documenting malignancy were available for 15 patients; 23 diagnoses were recorded more than one year after infusion. Among 1099 patients in the comparative analysis, male sex was associated with recorded malignancy diagnoses (adjusted odds ratio, 6.04; 95% confidence interval, 3.29–11.42; q < 0.001). No baseline laboratory variable was significantly associated with recorded malignancy diagnoses after correction for multiple testing. Conclusions: Gastrointestinal findings and malignancy diagnoses were documented in this treatment cohort. The association with male sex requires independent confirmation. These findings do not establish cancer incidence or a causal effect of IV iron.

DiagnosticsVol. 16(22)
Good health and well-being
Iron Metabolism and Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon